The Treatment of Capillary-Venous Malformations Using a New Fibrosing Agent

Riché, M C; Hadjean, E; Tran-Ba-Huy, Patrice; Merland, J J

doi:10.1097/00006534-198305000-00003

Cited by 59 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of the agent is related to the presence of 60% ethanol in its composition [8]. Pure ethanol deserves highlighting because of its potent fibrosing action, known and controllable side effects, low cost and ease of availability [7,24,25].…”

Section: Discussionmentioning

confidence: 99%

“…Percutaneous injection of liquid agents with sclerosing action into the lesion has been reported to be the therapeutic method of choice [6,7,8]. Pure alcohol is considered to be the most powerful and effective sclerosing agent [9], but its use at high doses may cause local and systemic complications, thus making this a high-risk treatment [10,11,12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ethanol Sclerotherapy of Superficial Venous Malformation: A New Procedure

et al. 2010

View full text Add to dashboard Cite

Background: Superficial venous malformations (SVM) are the most frequent vascular malformations. Outpatient percutaneous treatment with ethanol injection has rarely been described. Objective: To analyze the results from treating SVM patients with ethanol sclerotherapy. Methods: 81 patients were followed up prospectively over a median period of 18 months. 47 were female and 34 were male with a median age of 21 years. Most of the lesions were located in the limbs and the main symptom reported was pain. Each patient underwent fortnightly alcohol injection sessions. Results: The lesions and the symptoms completely disappeared or improved in 77 patients. There were no complications in 64 patients, while 11 presented a small skin ulcer, 3 hyperpigmentation and 3 paresthesia. Conclusion: Ethanol sclerotherapy for SVM patients was effective, with a low complication rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ethanol Sclerotherapy of Superficial Venous Malformation: A New Procedure

et al. 2010

View full text Add to dashboard Cite

show abstract

“…However, with reduced dosing first established in LMs (e.g., less than 1 mg/kg per session, more than 2 weeks between sessions, and no more than 5 mg/kg lifetime), this complication has not yet been reproducibly identified. [83][84][85][86][87] Other currently used or historically significant sclerosant agents in the treatment of VMs include ethanolamine oleate, 65,[88][89][90] sodium morrhuate, 56 and alcoholic solution of zein (Ethibloc, Ethicon, Norderstedt, Germany), 50,[91][92][93] to name a few.…”

Section: Technique Of Sclerotherapy For Venous Malformationsmentioning

confidence: 99%

A Step-by-Step Practical Approach to Imaging Diagnosis and Interventional Radiologic Therapy in Vascular Malformations

Legiehn

Heran

2010

Semin intervent Radiol

110

View full text Add to dashboard Cite

Within vascular anomalies, vascular malformations are those present at birth that grow with the patient and exhibit abnormal dilated vascular channels lined by mature endothelium. Vascular tumors, the other group of vascular anomalies, demonstrate endothelial hypercellularity. Vascular malformations are further divided into low-flow varieties (capillary, venous, and lymphatic malformations) and high-flow varieties (arteriovenous malformation and fistula). All malformations exhibit a predictable group of clinical patterns that vary in severity and rate of progression. The interventional radiologist must incorporate this clinical data with characteristic ultrasound and magnetic resonance findings to arrive at a diagnosis. One must then decide in a multidisciplinary fashion, based on objective clinical criteria and image-based morphology, if the patent is a candidate for intervention. Sclerotherapy is a technique used to treat vascular malformations whereby an endothelial-cidal agent is introduced into the endoluminal compartment to initiate vascular closure. The high flow rate of an arteriovenous malformation requires the incorporation of superselective transarterial, direct, and transvenous access with flow reduction techniques to deliver adequate dose of sclerosant and embolic to the nidus. Satisfactory outcomes are seen in over half of all malformations patients. Similar treatment-related complications are seen between malformations but are lowest in lymphatic and highest in arteriovenous malformations.

show abstract

“…1 Ethibloc is a thrombogenic and fibrogenic agent licensed for vascular embolization and surgical pancreatic duct occlusion. [20][21][22] Ethibloc is an emulsion including an alcoholic solution of zein, a contrast medium; 145 mg oleum papaveris per millimeter of alcohol (which is responsible for its soft consistency); and 6 mg propylene glycol per millimeter of alcohol to provide sterility. The viscosity at 37°C is 200 cp, compared with 10 cp for a conventional water-soluble contrast medium.…”

Section: Direct Ethibloc Injectionmentioning

confidence: 99%

“…22 The high viscosity allows for good filling of the cyst and makes the risk of embolization of the draining venous system unlikely. 20,23 Bone cysts are injected under general anesthesia. 1 Because of the fibrotic properties of Ethibloc, the procedure must be done at least 2 weeks after a previous surgery for histology.…”

Section: Direct Ethibloc Injectionmentioning

confidence: 99%